Drug Discovery, Pharmaceuticals & Cannabis Testing
Summary
With the Rapid Small-Scale Oxidation Test, the RapidOxy 100 offers a quick, easy, and reliable method to investigate formulas and products containing cannabinoids with regards to oxidation stability and product quality. The unique measuring principle leads to a signifi cantly reduced measuring time for the described investigations. Additionally, the straightforward principle gives rise to many further possibilities to access the oxidative behaviour of samples. By evaluating the pressure/time curve with OxyLogger 100 further, you can conduct automatic calculations of consumption, activation energy, and much more. Major benefi ts are its ease of use and fully automatic measurements. Since weighing in the sample is the only manual step, you minimise error sources as well. Independent from sample consistency, no sample preparation is necessary prior to the measurement. Therefore, you can investigate the oxidative behaviour of a sample as a whole.
References 1. Difonzo G., et al. 2018. Food Research International, 108: 48–56.
2. Guitard, R., Nardello-Rataj, V.*, Aubry*, J.M. 2016. International Journal of Molecular Science, 17: 1220.
3, H82IA016EN-A (Chia Seed Oil)
https://www.anton-paar.com/corp-en/services-support/ document-fi nder/application-reports/oxidation-stability-of-chia-seeds/
4. Edinger, C. 2023, Oils and Fats International, 39: 40.
5. H82IA008EN-A (Cocoa Mass)
https://www.anton-paar.com/corp-en/services-support/ document-fi nder/application-reports/oxidation-stability-of-cocoa-mass-and-vanilla-extracts/
6. XPAIA136EN-A (Food Powder)
https://www.anton-paar.com/corp-en/services-support/ document-fi nder/application-reports/ebook-mfi -food-powders-fi eld-guide-to-food-powder- characterization/
Read, Share and Comment on this Article, visit:
www.labmate-online.com Revolutionising neuromuscular disease research through 3D modelling
A recent case study published by AMSBIO highlights ground-breaking research in neuromuscular diseases. Led by Dr Roger Kamm at the Massachusetts Institute of Technology (MIT), this project focuses on developing a 3D microfluidic neuromuscular platform for modelling Motor Neuron Diseases (MNDs).
MNDs, particularly amyotrophic lateral sclerosis (ALS), remain a significant medical challenge with a limited life expectancy of 2 to 5 years. The complexity of these diseases and a lack of in-depth understanding have hindered effective treatments.
MIT researchers have made notable progress using CELLBANKER® 1 and STEM-CELLBANKER® cryopreservation media from AMSBIO. These advancements have the potential to transform drug discovery and enhance our comprehension of MND development.
Dr Kamm emphasised that previous MND drug discovery methods often overlooked the role of skeletal muscle cells. The newly developed 3D neuromuscular model presents a broader perspective on pathology and offers a novel path to identify treatments that target both motor neurons and muscle cells, addressing the complex nature of MNDs.
The research protocol features a microfluidic chip with separate compartments for each cell type, closely mimicking living tissue. Induced pluripotent stem cells (iPSCs) from healthy donors or ALS patients were differentiated into neural stem cells, then expanded and cryogenically preserved using STEM- CELLBANKER® from AMSBIO.
This innovative approach holds great promise to tailor treatments to individual genetics and drug responses, enhancing effectiveness while minimising side effects. By providing a more accurate disease representation, the 3D neuromuscular model may accelerate drug discovery and streamline the transition from laboratory research to clinical applications.
For the full case study, please visit
ilmt.co/PL/ymnQ
AMSBIO’s CELLBANKER® series of cell freezing media enables the stable long-term storage of cells. Its unique formulation ensures stable cryopreservation and high viability after freeze-thaw procedures, making it a trusted solution for storing any cell type, including sensitive cell lines. This series offers various formulations, providing high cell viability (>90%) in serum, serum-free, GMP, and DMSO-free formats.
More information online:
ilmt.co/PL/0QeJ 61489pr@reply-direct.com AI-enhanced drug design software enters early access program
DeepMirror, a University of Cambridge spin-out, introduces its Early Access Programme for intuitive design software dedicated to discovering innovative therapeutic drugs. Following a successful closed beta program, the software enables chemists to incorporate AI, enhancing productivity and creativity in therapeutic drug discovery.
This ground-breaking product offers users AI-driven insights to refine and expedite molecular design across the drug discovery pipeline. The secure and user-friendly interface simplifies AI-powered drug discovery, making it as intuitive as using a spreadsheet.
Traditionally, AI-enabled drug discovery collaborations involve extensive coordination between pharmaceutical and AI companies, resulting in prolonged waiting times and resource-intensive efforts on both ends. DeepMirror addresses this challenge by empowering R&D teams to conduct AI-driven research independently, with seamless workflow integration and without the need for external collaborations or significant internal developments.
DeepMirror’s mission is to accelerate the drug discovery process, particularly in Hit-to-Lead and Lead Optimisation phases. The software predicts crucial properties such as drug binding, (bio-)activity, and toxicity, leveraging user data and proprietary curated databases. Laboratory results further refine predictions, generating novel drug candidates for experimentation and potentially expediting the drug discovery process by up to four times, as estimated by the Wellcome Trust and the Boston Consulting Group.
Dr Max Jakobs, Co-Founder and CEO of DeepMirror, stated: “Our mission is to make AI-powered drug design as simple as browsing the web. After 12 months of development and a successful beta testing programme, we are inviting researchers to use our secure and user-friendly AI platform for drug design. DeepMirror has already proven instrumental in active drug discovery programs, leading to the discovery of novel lead series and inspiring the synthesis of new compounds.”
Dr Andrew McTeague, Senior Scientist, Medicinal Chemistry at Morphic Therapeutic, , said: “DeepMirror is a huge step forward in the democratization of machine learning models and their application in drug discovery. Its user-friendly interface enables medicinal chemists of all levels to deploy this powerful approach in a fraction of the time. The ability to apply DeepMirror’s platform to any desired endpoint empowers its users to make more informed decisions faster, improving the efficiency of our DMTA cycles.”
More information online:
ilmt.co/PL/d7JK 61866pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
